ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 606

Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients

Paul Studenic1, Farideh Alasti1, Josef S. Smolen2,3, Helmuth Haslacher4 and Daniel Aletaha5, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 32nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 4Laboratory Medicine, Medical University Vienna, Vienna, Austria, 5Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disease Activity, Kidney, methotrexate (MTX) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Methotrexate (MTX) and leflunomide are categorized
as DMARDs of first choice in treating rheumatoid arthritis patients. MTX should
be used cautiously in patients with impaired kidney function, but treatment
with MTX may also show an increased effectiveness in these patients, because of
accumulation. If MTX is contraindicated, for instance because of more severely
impaired kidney function, leflunomide can be used without dose adjustment. We
aimed to explore the role of the kidney function for the 6 month treatment
response to either methotrexate or leflunomide in RA patients.

 Methods:

We
selected patients from a longitudinal RA database, who started MTX monotherapy
or leflunomide treatment and had clinical follow ups over at least 6 months. In
a multivariable regression analyses, we used change in the simplified disease
activity index (SDAI) after 6 months as dependent variable, and baseline SDAI,  creatinine (or glomerular filtration rate),
and MTX dose as independent variables.

Results:

We
identified 256 patients starting MTX (80% female, 59% rheumatoid factor, RF,
positive; mean±SD:
SDAI: 17.2
±12, creatinine:
0.83±0.14 mg/dl, glomerular filtration rate (GFR): 83±22 ml/min, end MTX dose:
20.6±6.1) and as comparator group 80
patients starting a treatment of at least 6 months with leflunomide (86%
female, 57% RF positive, mean±SD SDAI: 13.6±8.8, creatinine:0.85±0.23,
GFR: 88±53).

Regression analyses in the
MTX cohort showed that that, after adjusting for MTX dose, higher creatinine
was associated with higher SDAI response after 6 months of treatment (p=0.029).
Analogously, in a separate analysis lower GFR was also significantly associated
with larger clinical improvement (p=0.04) (Figure).
SDAI response in patients with impaired kidney function and lower MTX dose
(GFR <75ml/min and <20mg of MTX, respectively) was similar to patients with
normal kidney function and higher MTX dose (GFR >75ml/min and ≥25mg of
MTX). In patients treated with leflunomide,
creatinine as well as GFR were not associated with SDAI change after 6 months
of treatment (p=0.585, p=0.962, respectively).

Figure: Regression
splines for SDAI response at 6 months of MTX treatment (blue with confidence
intervals) and leflunomide (red dotted with CI) predicted by glomerular
filtration rate

Conclusion:

We demonstrated here that patients with impaired renal
function seem to benefit in terms of SDAI response during treatment with
methotrexate. This was not found in patients treated with leflunomide. Higher
treatment responses in patients with impaired kidney function indicate
increased clinical benefit. This could also indicate room for higher MTX doses,
which are historically limited to 25mg/week, in patients with normal kidney
function and accompanied folate substitution.


Disclosure: P. Studenic, None; F. Alasti, None; J. S. Smolen, None; H. Haslacher, None; D. Aletaha, None.

To cite this abstract in AMA style:

Studenic P, Alasti F, Smolen JS, Haslacher H, Aletaha D. Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/impaired-kidney-function-improves-treatment-response-after-6-months-of-methotrexat-treatment-in-rheumatoid-arthritis-patients/. Accessed May 16, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impaired-kidney-function-improves-treatment-response-after-6-months-of-methotrexat-treatment-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.